HC Wainwright Analysts Raise Earnings Estimates for FDMT

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - HC Wainwright lifted their Q2 2025 earnings estimates for 4D Molecular Therapeutics in a report issued on Monday, May 12th. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($0.89) per share for the quarter, up from their previous estimate of ($0.93). HC Wainwright currently has a "Buy" rating and a $36.00 target price on the stock. The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for 4D Molecular Therapeutics' Q3 2025 earnings at ($0.92) EPS, Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($3.62) EPS, FY2026 earnings at ($3.84) EPS, FY2027 earnings at ($4.15) EPS, FY2028 earnings at ($3.90) EPS and FY2029 earnings at ($2.65) EPS.

FDMT has been the topic of a number of other reports. Royal Bank of Canada cut their target price on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating on the stock in a research note on Monday, March 3rd. Bank of America cut their target price on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating on the stock in a research note on Monday, March 10th. The Goldman Sachs Group cut their target price on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Weiss Ratings restated a "sell (e+)" rating on shares of 4D Molecular Therapeutics in a research note on Saturday. Finally, Barclays cut their target price on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, 4D Molecular Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $29.56.

4D Molecular Therapeutics Stock Performance

FDMT stock opened at $3.27 on Wednesday. The company's 50 day moving average price is $3.35 and its 200 day moving average price is $5.20. 4D Molecular Therapeutics has a fifty-two week low of $2.24 and a fifty-two week high of $28.93. The firm has a market capitalization of $151.48 million, a price-to-earnings ratio of -1.15 and a beta of 2.87.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.02).

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several hedge funds have recently added to or reduced their stakes in FDMT. Barclays PLC increased its stake in 4D Molecular Therapeutics by 141.0% in the third quarter. Barclays PLC now owns 114,848 shares of the company's stock valued at $1,241,000 after purchasing an additional 67,202 shares during the last quarter. Marquette Asset Management LLC purchased a new position in 4D Molecular Therapeutics in the fourth quarter valued at approximately $116,000. Peapod Lane Capital LLC purchased a new position in shares of 4D Molecular Therapeutics during the fourth quarter worth approximately $806,000. Rhumbline Advisers grew its position in shares of 4D Molecular Therapeutics by 5.3% during the fourth quarter. Rhumbline Advisers now owns 73,431 shares of the company's stock worth $409,000 after acquiring an additional 3,675 shares during the last quarter. Finally, Proficio Capital Partners LLC grew its position in shares of 4D Molecular Therapeutics by 100.0% during the fourth quarter. Proficio Capital Partners LLC now owns 20,000 shares of the company's stock worth $111,000 after acquiring an additional 10,000 shares during the last quarter. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.